Study on Using Enzalutamide for Early Stage Androgen Receptor Positive Triple Negative Breast Cancer

Inclusion Criteria

• Have stage 1, 2, or 3 invasive breast cancer that is triple negative, meaning it does not have certain hormone receptors.
• Have cancer that tests positive for androgen receptors (AR+).
• Have completed surgery, chemotherapy, or radiation at least 4 weeks ago, with any side effects reduced to mild levels.
• Be within 6 months of finishing initial breast cancer treatment.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Be a woman aged 18 or older.
• Be able to swallow the study medication and follow study requirements.
• Women who can become pregnant must have a negative pregnancy test and agree to use two forms of birth control during the study and for 3 months after.
• Not be breastfeeding during the study and for at least 3 months after the last dose of the study drug.

Exclusion Criteria

• Have any serious health conditions or infections that would make participating in the study unsafe.
• Have stage 4 breast cancer or cancer that has spread to other parts of the body.
• Have had another invasive cancer in the past 5 years, except for certain skin cancers or very early-stage cancers.
• Have low blood cell counts or low hemoglobin levels.
• Have high levels of certain liver enzymes or bilirubin unless due to a non-cancerous condition.
• Have poor kidney function.
• Have a history of seizures or conditions that increase the risk of seizures.
• Have digestive issues that affect absorption of medication.
• Have allergies to the study drug or its ingredients.